Novavax starting trial of COVID-19 vaccine in South Africa

/ / News

Novavax said it’s beginning a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, its COVID-19 vaccine candidate. The Bill & Melinda Gates Foundation providing $15 million grant toward trial, said Novavax, which last week agreed to sell its vaccine to the U.K. government if successful. “Because South Africa is experiencing a winter surge of COVID-19 disease, this important Phase 2b clinical trial has the potential to provide an early indication of efficacy, along with additional safety and immunogenicity data for NVX-CoV2373,” said Gregory Glenn, president of research and development at Novavax.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.